Journal
CLINICAL INFECTIOUS DISEASES
Volume 71, Issue 4, Pages 1102-1105Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciz1151
Keywords
bezlotoxumab; Clostridioides difficile; recurrence; extension phase
Categories
Funding
- Merck Sharp Dohme Corp.
Ask authors/readers for more resources
From Monoclonal Antibodies for C. difficile Therapy II, no participants (n = 0/69) with a sustained clinical cure through 12 weeks following bezlotoxumab infusion experienced recurrent Clostridioides difficile infection (rCDI) after 9 months (versus actoxumab + bezlotoxumab, n = 2/65; versus placebo, n = 1/34). Bezlotoxumab's efficacy appears to be due to prevention rather than delayed onset of rCDI.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available